Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
Atherosclerosis, Kidney Failure
About this trial
This is an interventional treatment trial for Atherosclerosis focused on measuring Kidney transplant, Renal transplant, Immunosuppression, Atherosclerosis, Graft Rejection
Eligibility Criteria
Inclusion Criteria: At least one of the following characteristics: History of dialysis for at least 3 years. History of diabetes for at least 5 years. Hypertension or ischemic nephropathy as a cause of the end stage renal disease or loss of the first transplant. History of coronary artery disease, stroke, myocardial infarction, or amputation for vascular disease. Exclusion Criteria: History of malignancy within the last 5 years (except adequately treated skin cancer). Recipients of non-renal organ transplant. Active gastrointestinal disease that may interfere with drug absorption. Active HIV, hepatitis B or C infection. Women who are pregnant or breastfeeding.
Sites / Locations
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
1
2
Tacrolimus + MMF + Steroids
Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant